Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)
| Autor: | Kenna D. Payne, Amrita Das, Michelle Ndiulor, Ronald G. Hall |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Methicillin-Resistant Staphylococcus aureus Dose-Response Relationship Drug 030106 microbiology Administration Oral General Medicine Staphylococcal Infections Anti-Bacterial Agents 03 medical and health sciences 0302 clinical medicine Drug Resistance Bacterial Animals Humans Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics |
| Zdroj: | Expert review of clinical pharmacology. 11(2) |
| ISSN: | 1751-2441 |
| Popis: | Methicillin-resistant Staphylococcus aureus (MRSA) is a problematic pathogen in both outpatient and inpatient settings. Research to optimize the dosing of these agents is needed to slow the development of antimicrobial resistance and to decrease the likelihood of clinical failure. Areas covered: This review summarizes the available data for orally administered antimicrobials routinely used as monotherapy for MRSA infections. We make recommendations and highlight the current gaps in the literature. A PubMed (1966 - Present) search was performed to identify relevant literature for this review. Expert commentary: There is a vast divide in the amount of pharmacokinetic/pharmacodynamic data to guide dosing decisions for older MRSA agents compared with the oxazolidenones. Five-year view: Additional retrospective data will become available for the older MRSA agents in severe MRSA infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|